Warwick’s MultiCell Technologies Inc., a cellular engineering and research organization, has just signed a collaborative research agreement with Pfizer Inc. Specific terms were not disclosed.
MultiCell focuses on the development and commercialization of hepatic (liver) cells, cell lines, and biologics for use in diagnostic and therapeutic applications. MultiCell’s cellular products enable cell transplantation, vaccine development and therapeutic protein production. The company will develop cell based toxicological and drug screening tests for use by the pharmaceutical industry and others.
Beyond Cash Donations: How New Forms of Giving Are Transforming Not-for-Profit Accounting
Evolving Funding Landscape for Not-for-Profits Not-for-profit organizations are being asked to do more with less,…
Learn More
The agreement with Pfizer involves validation of MultiCell’s immortalized liver cells to predict, among other things, the toxicological and therapeutic properties of drug candidates.
